Search Results
Your search for all items matches 36992 pages
Showing 1 - 50
Adam J. Schoenfeld, MD, on Advanced Lung Cancer: Pumitamig Plus Elfetabart Drozuntecan
Adam J. Schoenfeld, MD, of Memorial Sloan Kettering Cancer Center, discusses findings from BNT324-01, an ongoing global phase Ib/II trial looking at pumitamig, an investigational PD-L1 × VEGF-A bispecific antibody, combined with elfetabart drozuntecan (BNT324/DB-1311), an investigational...
Pembrolizumab/Olaparib Strategy in BRCA-Nonmutated Advanced Ovarian Cancer
A pembrolizumab/olaparib strategy significantly improved progression-free survival in patients with newly diagnosed BRCA-nonmutated advanced epithelial ovarian cancer, although overall survival was not improved. Ignace Vergote, MD, PhD, and colleagues reported results from the phase III...
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Cancer death rates fell for both men and women from 2019 to 2023, continuing a downward trend that has lasted more than 20 years, according to the 2026 Annual Report to the Nation on the Status of Cancer, published by Henley et al in the journal Cancer. The continued decline in cancer deaths is...
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence?
Among patients with ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery, negative surgical margins narrower than 2 mm were not associated with a significantly higher risk of ipsilateral recurrence compared with margins of at least 2 mm—except among patients younger than age...
IARC Panel Provides International Determination on Lung Cancer Screening's Benefits and Harms
The International Agency for Research on Cancer (IARC) has published a comprehensive international evaluation on lung cancer screening in The New England Journal of Medicine. Screening has emerged as a complementary approach to tobacco control and other methods for preventing lung cancer to reduce...
Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer?
Colorectal cancer, once thought of as mainly a disease of the aging, is rising in younger adults by nearly 3% per year and is now a leading cause of cancer-related death among individuals under the age of 50.1 According to the American Cancer Society, in 2026, nearly 159,000 individuals will be...
FDA Launches Effort to Expand Scientific Expertise, Consumer Voice to Advisory Committees
The U.S. Food and Drug Administration (FDA) recently announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees. The FDA is publishing two Federal Register notices: one seeking qualified scientific, technical, and...
Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis
The results of the randomized NHS-Galleri trial reported by Sasieni et al in The New England Journal of Medicine showed that annual screening with a blood-based multicancer early detection test added to usual care did not result in a significantly lower incidence rate of stage III or IV cancers...
Cleveland Clinic London Appoints Oncology Vice Chief
Cleveland Clinic London has appointed Heather Shaw, MD, FRCP, as Oncology Vice Chief, reinforcing the organization’s commitment to expanding access to advanced, multidisciplinary cancer care in the United Kingdom. Dr. Shaw will lead oncology strategy and service development across Cleveland Clinic...
NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress
The biennial World Cancer Congress, organized by the Union for International Cancer Control (UICC), is the leading international conference on cancer control, bringing together researchers, clinicians, advocates, policymakers, and people with lived experience from more than 120 countries. Two...
SYMPRO-Lung: Could Weekly PRO Symptom Monitoring Improve Survival Outcomes in Any-Stage Lung Cancer?
According to results from a post hoc analysis of the SYMPRO-Lung trial published in The Lancet Oncology, weekly patient-reported outcome (PRO) symptom monitoring may be associated with improved long-term overall survival among patients across all stages of lung cancer. Hassing et al reported that...
Anne Chiang, MD, PhD, on Targeting B7-H3 in Second-Line SCLC Treatment: Novel ADCs
Anne Chiang, MD, PhD, of Yale University School of Medicine, provides commentary on two China-based phase III studies presented in Presidential Symposium 1: TAISHAN-02, which looked at the antibody-drug conjugate (ADC) tambotatug pelitecan vs topotecan among patients with relapsed small cell lung...
Depression Increases Cancer-Specific Mortality Risks in Common Cancers
Depression in patients with cancer may be associated with a higher mortality risk, according to findings from a large SEER-Medicare analysis presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 195). The analysis found that psychotherapy soon after...
Mindfulness and Tai Chi May Improve Symptoms After Cancer Treatment
Mindfulness-based cancer recovery and Tai Chi/Qigong were associated with improvements in fatigue and pain interference among distressed individuals who had completed cancer treatment, with Tai Chi/Qigong also improving sleep quality, according to findings from the Mindfulness and Tai Chi for...
Real-World Data Indicate Lower Adherence Rates for Breast Cancer Endocrine Therapy When Radiation Therapy Is Omitted
Many patients with early-stage breast cancer do not consistently maintain the long-term hormone therapy prescribed after lumpectomy, a large U.S. insurance claims analysis indicates. Findings provide important real-world context for treatment approaches that consider omitting radiation therapy,...
Ricardo Sales dos Santos, MD, PhD, on Mobile Lung CT Screening in Resource-Limited Settings: BRELT3
Ricardo Sales dos Santos, MD, PhD, of the ProPulmão Institute, discusses data from the Third Brazilian Early Lung Cancer Trial (BRELT3). The study found low-dose computed tomography (CT) lung cancer screening using a mobile unit is feasible in socially vulnerable populations in resource-limited...
Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer
Five-treatment stereotactic body radiation therapy (SBRT) may offer an effective alternative to surgery for patients with localized prostate cancer. In long-term follow-up findings from the phase III PACE-A trial presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting...
Ultra–Low-Dose Radiation Therapy May Relieve Bone Pain From Multiple Myeloma
A short course of ultra–low-dose radiation therapy relieved painful bone lesions from multiple myeloma for patients in a multi-institutional phase II clinical trial. The findings suggest that a lower-intensity approach could help ease patients’ pain without interrupting other treatment and with few ...
Cancer Statistics 2026: What Every Medical Oncologist Should Know
Cancer remains a dominant driver of morbidity and mortality globally and in the United States and continues to impose a substantial and evolving public health burden. Although age-adjusted cancer mortality has declined steadily for more than 3 decades, demographic aging and population growth have...
Short-Course SBRT Better Preserves Physical Function Before Pancreatic Cancer Surgery
Patients preparing for pancreatic cancer surgery maintained better physical function and experienced less fatigue with 5 treatments of stereotactic body radiation therapy (SBRT) than with 28 treatments of conventional radiation therapy given with chemotherapy, according to findings of a randomized...
New Prognostic Model May Improve Risk Classification in Metastatic Clear Cell RCC
A new prognostic model developed for the checkpoint inhibitor era showed better discrimination of survival outcomes in patients with previously untreated metastatic clear cell renal cell carcinoma (RCC) than the widely used International Metastatic RCC Database Consortium (IMDC) model. The...
Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma
Longer follow-up from a phase I trial of intracerebroventricular bivalent CAR T-cell therapy in recurrent glioblastoma showed no long-term or delayed-onset toxicities, with a median overall survival of 12.0 months, according to updated data presented at the 2026 ASCO Annual Meeting. The...
Adding Targeted Immunotherapy to Pembrolizumab in Recurrent or Metastatic HPV16-Positive Head and Neck Squamous Cell Carcinoma
Based on the results of the nonrandomized multicenter phase II VERSATILE-002 trial reported in JAMA Oncology, a regimen adding the human papillomavirus type 16 (HPV16)-targeted immunotherapy PDS0101 to pembrolizumab demonstrated antitumor activity in immune checkpoint inhibitor–naive patients with...
SRS Is a "Reasonable Option" for Patients With SCLC and Brain Metastases
Stereotactic radiosurgery demonstrated a prolonged overall survival compared with hippocampal-avoidant whole-brain radiotherapy with memantine in patients with small cell lung cancer (SCLC) and brain metastases, according to phase III study findings presented at the 2026 American Society for...
Fractionated SRS Approach Improves Outcomes for Patients With Resected Large Brain Metastases
Fractionated stereotactic radiosurgery after resection improves surgical bed control compared with single-fraction stereotactic radiosurgery for patients with large brain metastases, according to findings from a phase III trial presented at the 2026 American Society for Radiation Oncology (ASTRO)...
Phase III Trial Compares HER2-Directed Antibody-Drug Conjugates in Advanced Breast Cancer
According to findings from a phase III randomized trial reported by Zhang et al in the Journal of Clinical Oncology, the novel HER2-directed antibody-drug conjugate trastuzumab botidotin significantly prolonged progression-free survival compared with ado-trastuzumab emtansine (T-DM1) in patients...
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
On September 24, the U.S. Food and Drug Administration (FDA) approved the HIF-2α inhibitor belzutifan (Welireg) in combination with the tyrosine kinase inhibitor lenvatinib (Lenvima) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following treatment with a PD-1 or ...
Building Momentum: ASCO’s Geriatric Oncology CoP
The ASCO Geriatric Oncology Community of Practice (geriatric oncology CoP) convened for its first in-person meeting at McCormick Place in Chicago in May 2026. Since its inception in 2022, the geriatric oncology CoP has brought together clinicians, researchers, trainees, and patient advocates...
I Wasn’t Expecting Cancer at 22
Before I was diagnosed with advanced stage ovarian ependymoma, in 2025, when I was just 22, I didn’t know anything about cancer. I knew a few older adults who had had cancer, but that was the extent of my knowledge about the disease. Even to this day, I’m not sure I’ve completely wrapped my head...
Guideline Update Recommends Tailoring Breast Cancer Surveillance Based on Recurrence Risk
ASCO has published a guideline update offering clinicians new recommendations for breast cancer follow-up and surveillance after primary treatment.1 For this patient population, determining the optimal frequency and timing of visits can be a challenge, according to Expert Panel Co-Chair Maryam...
Jonathan W. Goldman, MD, on SCLC: Tarlatamab Extended-Interval Dosing Regimens
Jonathan W. Goldman, MD, of the University of California, Los Angeles, reviews findings from the phase II DeLLphi-309 study, which examined the efficacy, safety, and pharmacokinetics of tarlatamab extended-interval dosing regimens (20 mg every 3 weeks and 30 mg every 4 weeks) in comparison to the...
FDA Advisory Committee Votes in Favor of Approval of Multi-Cancer Early Detection Test
A multi-cancer early detection test named Galleri from the health-care company GRAIL received a favorable vote from the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee. The Committee voted for approval of the premarket...
Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors
The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
A multimodal artificial intelligence (AI) model incorporating multiscale histopathology features was able to predict recurrence risk in patients with early-stage hormone receptor–positive and HER2-negative breast cancer more accurately than the 21-gene recurrence score, Oncotype DX, according to...
How One Nonprofit Is Providing Access to a Discontinued Investigational Drug for Children With a Rare Form of AML
Blood Cancer United (formerly the Leukemia & Lymphoma Society) recently announced it had acquired the remaining supply and rights to the investigational agent luveltamab tazevibulin, an antibody drug conjugate targeting the folate receptor-1 alpha (FOLR1) molecule, from the drug’s manufacturer, ...
As AI Advances, How Will the Clinician’s Role Change?
Peter Clardy, MD, of Google for Health, described a fundamental challenge facing clinicians in the artificial intelligence (AI) era: AI capabilities are advancing rapidly at the same time clinicians are being asked to make decisions based on an ever-expanding volume of information. In oncology...
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
New updates to the College of American Pathologists’ (CAP) Cancer Protocols will affect breast cancer biomarker reporting and molecular testing for gastrointestinal stromal tumors (GISTs), reflecting advances in precision oncology and laboratory accreditation. The updates are part of revisions to...
Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC
Daraxonrasib produced responses in more than 30% of patients with previously treated advanced RAS-mutant non–small cell lung cancer (NSCLC), with activity observed across multiple RAS mutations in a phase I/II study. Results from Kathryn C. Arbour, MD, David S. Hong, MD, and colleagues were...
Tambotatug Pelitecan May Improve Survival Outcomes in Relapsed SCLC
The B7-H3–targeting antibody-drug conjugate tambotatug pelitecan significantly improved overall survival compared with topotecan in patients with small cell lung cancer (SCLC) that had progressed after first-line platinum-based therapy, according to results of the phase III TAISHAN-302 trial...
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
On September 23, 2026, the U.S. Food and Drug Administration (FDA) approved lirafugratinib (Lyrfigtu) for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other...
Trastuzumab Rezetecan Improves Progression-Free Survival in Chemotherapy-Refractory HER2-Positive Advanced Colorectal Cancer
The human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugate trastuzumab rezetecan significantly improved progression-free survival and produced higher response rates compared with standard-of-care therapy in patients with chemotherapy-refractory, HER2-positive, RAS/RAF...
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Adding venetoclax to dose-adjusted EPOCH-R (DA-EPOCH-R) did not improve progression-free survival and resulted in excess toxicity and mortality among patients with newly diagnosed double-hit lymphoma, prompting early closure of the double-hit lymphoma cohort of the randomized ALLIANCE A051701...
Neoadjuvant Anbenitamab/Chemotherapy Combination Improves Response in ERBB2-Positive Breast Cancer
Neoadjuvant treatment with the ERBB2-biparatopic antibody anbenitamab plus a solvent-free albumin-bound docetaxel formulation (HB1801) significantly improved total pathologic complete response vs conventional therapy with trastuzumab plus pertuzumab and a taxane (THP) in patients with early or...
Germline EGFR T790M Associated With Significant Lung Cancer Risk
Researchers have found a significantly increased risk of lung cancer in individuals with an EGFR T790M germline variant, about 25 times higher than in noncarriers, according to study findings published in Science. “Today, lung cancer screening is driven almost entirely by smoking history,” said...
Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC
Patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease progressed following PD-1/-L1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti–CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving...
Julia Rotow, MD, on Metastatic HER2-Mutant NSCLC: First-Line T-DXd
Julia Rotow, MD, of Dana-Farber Cancer Institute, discusses the primary results from the phase III DESTINY-Lung04 trial, which evaluated first-line trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, against pembrolizumab plus platinum chemotherapy in patients with...
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
Researchers have identified varying clinicopathologic characteristics and outcomes between patients with non–small cell lung cancer (NSCLC) and class II and III BRAF mutations, according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World...
ASCO Breakthrough Studies Target Supportive Care Problems That Can Derail Treatment
Three studies presented at the 2026 ASCO Breakthrough conference in Singapore focused on problems that can derail cancer care even when treatment is otherwise on track: nausea after starting morphine, continued smoking after a cancer diagnosis, and unrecognized frailty in older adults. Although the ...
AACR Releases Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 16th edition of its annual Cancer Progress Report. This comprehensive report provides current data on cancer incidence, mortality, and survivorship. It also outlines how basic, translational, and clinical cancer research and...
KEYNOTE-826: Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
Five-year follow-up from the phase III KEYNOTE-826 trial suggests a durable benefit with first-line pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, in patients with recurrent or metastatic cervical cancer, according to Hasegawa et al in JAMA Oncology. At the first...
